Subscribe
shutterstock_528642268-1
31 July 2019AmericasSarah Morgan

Alkermes settles with Amneal over opioid dependence treatment

Biopharmaceutical company  Alkermes has entered into a settlement and licence agreement with generic maker  Amneal Pharmaceuticals to resolve an inter partes review (IPR).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.

More on this story

Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory